JP2025516359A5 - - Google Patents
Info
- Publication number
- JP2025516359A5 JP2025516359A5 JP2024565274A JP2024565274A JP2025516359A5 JP 2025516359 A5 JP2025516359 A5 JP 2025516359A5 JP 2024565274 A JP2024565274 A JP 2024565274A JP 2024565274 A JP2024565274 A JP 2024565274A JP 2025516359 A5 JP2025516359 A5 JP 2025516359A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- alkyl
- group
- cancer
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339308P | 2022-05-06 | 2022-05-06 | |
| US63/339,308 | 2022-05-06 | ||
| US202263398752P | 2022-08-17 | 2022-08-17 | |
| US63/398,752 | 2022-08-17 | ||
| US202263429834P | 2022-12-02 | 2022-12-02 | |
| US63/429,834 | 2022-12-02 | ||
| US202363449728P | 2023-03-03 | 2023-03-03 | |
| US63/449,728 | 2023-03-03 | ||
| US202363454486P | 2023-03-24 | 2023-03-24 | |
| US63/454,486 | 2023-03-24 | ||
| PCT/US2023/020956 WO2023215449A1 (en) | 2022-05-06 | 2023-05-04 | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516359A JP2025516359A (ja) | 2025-05-27 |
| JP2025516359A5 true JP2025516359A5 (enExample) | 2026-05-01 |
Family
ID=86609470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565274A Pending JP2025516359A (ja) | 2022-05-06 | 2023-05-04 | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250288683A1 (enExample) |
| EP (1) | EP4519272A1 (enExample) |
| JP (1) | JP2025516359A (enExample) |
| AU (1) | AU2023264537A1 (enExample) |
| CA (1) | CA3252016A1 (enExample) |
| MX (1) | MX2024013312A (enExample) |
| WO (1) | WO2023215449A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023044046A1 (en) * | 2021-09-17 | 2023-03-23 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
| WO2023246924A1 (zh) * | 2022-06-24 | 2023-12-28 | 南京瑞初医药有限公司 | 苯并噻唑化合物及其应用 |
| EP4759810A1 (en) * | 2023-08-11 | 2026-06-17 | Beijing Suncell Bio-Medical Co., Ltd. | Protac targeting bcl-xl protein and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| WO2020163823A2 (en) | 2019-02-08 | 2020-08-13 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN112707900B (zh) | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CA3163593A1 (en) | 2020-01-15 | 2021-07-22 | Guangrong Zheng | Therapeutic agents and methods of treatment |
| CA3173843A1 (en) | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| WO2023044046A1 (en) | 2021-09-17 | 2023-03-23 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
-
2023
- 2023-05-04 AU AU2023264537A patent/AU2023264537A1/en active Pending
- 2023-05-04 US US18/858,971 patent/US20250288683A1/en active Pending
- 2023-05-04 WO PCT/US2023/020956 patent/WO2023215449A1/en not_active Ceased
- 2023-05-04 JP JP2024565274A patent/JP2025516359A/ja active Pending
- 2023-05-04 EP EP23727754.6A patent/EP4519272A1/en active Pending
- 2023-05-04 CA CA3252016A patent/CA3252016A1/en active Pending
-
2024
- 2024-10-28 MX MX2024013312A patent/MX2024013312A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025517642A5 (enExample) | ||
| JP2025516358A5 (enExample) | ||
| JP6823095B2 (ja) | 噴霧乾燥製剤 | |
| JP7466795B2 (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン | |
| JP7326622B2 (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| JP6547042B2 (ja) | 非選択的キナーゼ阻害剤 | |
| ES2761300T3 (es) | 3-[4-(7H-pirrolo[2,3-d]pirimidina-4-ilo)-1H-pirazol-1-ilo]octano- o heptano-nitrilo como inhibidores de JAK | |
| WO2021203768A1 (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP2021522276A5 (enExample) | ||
| JP2008525530A5 (enExample) | ||
| JP2023531709A5 (enExample) | ||
| JP2023506787A5 (enExample) | ||
| JP2023533203A5 (enExample) | ||
| JP2021507895A5 (enExample) | ||
| JP2023531495A5 (enExample) | ||
| JP2020534300A5 (enExample) | ||
| TW202116740A (zh) | 稠環嘧啶氨基化合物、其製備方法、藥物組合物及應用 | |
| JP2025516543A5 (enExample) | ||
| JP2022517110A5 (enExample) | ||
| JP2024546095A5 (enExample) | ||
| CN114404415A (zh) | 吲唑类化合物用于治疗银屑病的用途 | |
| JP2025500049A5 (enExample) | ||
| JP7854973B2 (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン | |
| WO2025094035A1 (en) | Toll-like receptor agonists and conjugates thereof | |
| WO2025067384A1 (zh) | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |